OPB-111077

DRUG6 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Korea Otsuka Pharmaceutical Co., Ltd., National University Hospital, Singapore, Hospital Universitario 12 de Octubre, Otsuka Pharmaceutical Co., Ltd.

Conditions

Acute Myeloid LeukemiaAdvanced Hepatocellular CarcinomaNPCRefractory TumorRelapsed or Refractory Diffuse Large B-cell LymphomaSolid TumorSolid Tumors

Phase 1

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

CompletedNCT01711034

Otsuka Pharmaceutical Development & Commercialization, Inc.Solid Tumors

Start: 2012-06-30End: 2015-12-31Updated: 2016-04-05

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

TerminatedNCT01942083

Korea Otsuka Pharmaceutical Co., Ltd.Advanced Hepatocellular Carcinoma

Start: 2013-05-29End: 2016-07-11Updated: 2017-05-09

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

CompletedNCT02250170

Korea Otsuka Pharmaceutical Co., Ltd.Solid Tumor

Start: 2014-10-23End: 2019-03-08Updated: 2019-09-10

Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia

CompletedNCT03197714

Hospital Universitario 12 de OctubreAcute Myeloid Leukemia

Start: 2017-09-07End: 2020-03-31Updated: 2021-02-15

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

CompletedNCT04049825

Otsuka Pharmaceutical Co., Ltd.Relapsed or Refractory Diffuse Large B-cell Lymphoma

Start: 2019-11-22End: 2026-01-19Updated: 2026-04-08

Phase 2

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

National University Hospital, SingaporeNPC, Refractory Tumor

Start: 2017-05-22End: 2020-11-30Target: 52Updated: 2017-06-15

Related Papers

Synergistic Antitumor Effect of a Novel First-in-Class Small Molecule OPB-111077 That Inhibits Mitochondrial Oxidative Phosphorylation in Combination with Alkylating Agent

Blood2024-11-051 citations

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Blood2023-11-021 citations

Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology2018-05-203 citations